Company / Named in our posts
VERAXA.
Follow VERAXAVERAXA develops next-generation antibody-based therapeutics, including bispecific ADCs and bispecific T cell engagers.[1]
01Deal
Deals on Carrywatch
Every deal that names VERAXA, and its role in each.
Voyager Acquisition Corp. / VERAXA
Voyager Acquisition Corp. and VERAXA enter business combination agreement
See deal detailsDeal Web
VERAXA and 1 firm it shares a posted deal with, and the path to any other firm.
News
Loading headlines.
Sources
As of 25 Oct 2026.
- 01VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
U.S. Securities and Exchange Commission · Researched 25 Oct 2026
Deal posts naming VERAXA:
- P01